Amarin Corp Plc (AMRN)

[Biobillionair]

Hi Nuke,
I agree MDVN is perhaps the best comparison...but it's still only prostate cancer, which has a very low kill rate. Cardiovascular disease has been the number one killer (perhaps bested by the FDA) for over 30+ years. I highly doubt MDVN saves overall health care dollars to even the smallest degree that Vascepa will achieve. "V" will be an all time record setter in $$$ sold, perhaps even doubling Lipitor. "V" limiting factor will eventually be a supply issue. Hopefully you can retire before November.
BB